News Agency
Men's Weekly

Inmagene Doses First Patient in Phase 2a Trial of IMG-007, an Anti-OX40 Monoclonal Antibody with an Extended Half-life, for the Treatment of Alopecia Areata

  • Written by PR Newswire
  • IMG-007 is a novel anti-OX40 monoclonal antibody (mAb) engineered for potentially once every 12 weeks dosing and an improved safety profile
  • IMG-007 is being evaluated for the treatment of alopecia areata (AA) and atopic dermatitis (AD)
  • An interim data readout in AA is expected in Q3 2024

SAN DIEGO, Oct. 13, 2023 /PRNewswire/ -- Inmagene...

Read more: Inmagene Doses First Patient in Phase 2a Trial of IMG-007, an Anti-OX40 Monoclonal Antibody with...

Improving Internal Feedback Loops Through CMS-Based Commenting and Versioning

Collaboration is essential for successful digital content creation. Unfortunately, in many companies, the feedback mechanism between marketing, design, product and development functions is less than cohesive. For example, feedback is left in email chains, instant chat messages, or within locked... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion